News | November 15, 2012

Biomedical Systems Awarded Patent for its Long-term ECG Monitoring to Diagnose Atrial Fibrillation

TruVue patented technology wirelessly transmits every heartbeat for up to 30 Days; provides physicians direct data access online

Biomedical Systems TruVue Wireless Ambulatory ECG Monitoring System

November 15, 2012 — The U.S. Patent and Trademark Office has awarded Biomedical Systems U.S. Patent Number 8301236 for its TruVue Wireless Ambulatory ECG Monitoring System. Biomedical Systems developed TruVue for the diagnosis and management of atrial fibrillation, considered the leading preventable cause of stroke affecting nearly three million Americans at a cost of $26 billion each year. The Centers for Disease Control and Prevention estimates the number of people impacted by atrial fibrillation to grow five times the current rate by 2050.

The patented TruVue technology records and wirelessly transmits every heartbeat for up to 30 days. Biomedical Systems houses the ECG information in its secure data center where certified cardiac technicians monitor and analyze abnormalities, post real-time reports and alert physicians to cardiac events. At any time, physicians can directly access information online — without working through support staff — to review any portion of the recorded ECG monitoring and trend reports detailing 24-hour heart rate and rhythm abnormalities.

“We offer the advantages of both a Holter and cardiac event monitor in one device to provide the most comprehensive long-term view of the heart rhythm,” said Jim Ott, chief technology officer, Biomedical Systems. “TruVue was created to help physicians accurately classify and assess atrial fibrillation and other complex arrhythmia. Our patented technology acquires and transmits every heartbeat for up to 30 days and immediately allows physicians access to information online —including both algorithm-triggered ECG-recordings and episodes recorded by patients.”

“Biomedical Systems has developed a revolutionary technology to assist in diagnosing and managing our atrial fibrillation patients,” said Carey S. Fredman, director, Electrophysiology Services, St. Luke’s Hospital, St. Louis, Mo. “TruVue gives me immediate access to review the onset and offset of sustained abnormal rhythms, giving me confidence to accurately diagnose my patients with AFib.”  

In addition to Afib monitoring, pharmaceutical and medical device companies are also employing TruVue to assess the cardiovascular safety and efficacy associated with new drugs and devices. In pharmaceutical clinical trials, for example, TruVue’s heart monitoring capabilities support the efficient and accurate capture of valid data during Phase 1 to 4 clinical studies or in post-marketing surveys.

For more information:

Related Content

CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
Overlay Init